Erectile dysfunction (ED) is a prevalent condition affecting millions of men worldwide, characterized by the inability to achieve or maintain an erection sufficient for sexual intercourse. As men seek effective treatments, considerations of cost-effectiveness become increasingly important. In this article, we explore how Suhagra 100 compares with other ED treatments in terms of both direct and indirect costs. As research and innovation progress in the field of ED treatment, ongoing evaluation of cost-effectiveness will guide healthcare providers and patients alike in making informed decisions regarding the most suitable treatment options. By prioritizing both clinical efficacy and financial considerations, individuals can manage their health effectively while maintaining quality of life and overall well-being.